Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder

CMAJ. 2024 Mar 17;196(10):E346-E347. doi: 10.1503/cmaj.149917-l.

Authors

Anees Bahji¹, Marlon Danilewitz², Matthew Sloan³, Victor Tang³, David Crockford¹

Affiliations

¹ Psychiatrist, Department of Psychiatry, University of Calgary, Calgary, Alta.
² Psychiatrist, Department of Psychiatry, University of Toronto, Toronto, Ont.
³ Psychiatrist, Centre for Addiction and Mental Health, Toronto, Ont.

No abstract available

Publication types

Letter

MeSH terms

Alcohol Drinking
Alcoholism* / drug therapy
Canada
Humans
Selective Serotonin Reuptake Inhibitors* / therapeutic use

Substances

Selective Serotonin Reuptake Inhibitors

Grants and funding

R25 DA037756/DA/NIDA NIH HHS/United States